Safinamide

A selective and reversible inhibitor of monoamine oxidase B (MAO-B, IC50=98 nM with greater than 100-fold selectivity over MAO-A) (1). It displays anticonvulsant activity (2) and protects against kainate-induced seizures and hippocampal neurodegeneration in rat models (3). Reduces overactive glutamatergic signaling via use-dependent sodium channel blockade (4). A novel therapeutic for Parkinson’s disease with multiple modes of action (5). Effective as an add-on to dopamine agonist therapy in early Parkinson’s Disease(6).

1. MS Strolin Benedetti et al. 1994 J. Pharm. Pharmacol. 46:814 2. RG Fariello et al. 1998 J. Pharmacol. Exp. Ther. 285:397 3. R Maj et al.1998 Eur. J. Pharmacol. 8 359:27 4. F Gardoni et al. 2018 J. Pharmacol. Exp. Ther. 2018 367:442 5. C Caccia et al. 2006 Neurology 67(7 Suppl. 2):S18 6. AH Schapira et al. 2013 Eur. J. Neurol. 20:271